A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
COVID-19, cytokine storm and sigma-1 receptors: potential treatments at hand?
[post]
2020
unpublished
Preserved Fulltext
Fluvoxamine, a usual SSRI antidepressant, has agonistic activity on Sigma-1 receptors in ER and inhibits IRE1, an important trigger of cytokine production; Sigma-1 receptor is a target of SARS-COV-2 protein Nsp6 and may start the cytokine storm.
doi:10.22541/au.159335613.31156244/v2
fatcat:6l3yd3s3xjgippo7rnko4o2jbq